Hemispherx Biopharma Announces the Completion of the Newly

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Hemispherx Biopharma Announces the Completion of the Newly Upgraded Alferon(R) Facility: Commercial Production of Alferon(R) is in the Final Stage Integrating Continuous Flow Manufacturing Technology

PHILADELPHIA, March 2, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announced today that its manufacturing site located in New Brunswick, New Jersey, presently configured at over 43,000 square feet, has completed its $8 million of upgrades. These upgrades will provide for a higher capacity, more cost effective manufacturing process for the production of Alferon N Injection®, the only FDA-approved natural alpha interferon. The added efficiency of the process has been accomplished by integrating continuous flow manufacturing technology throughout the process. This has led to improved cost efficiency, enhanced yields, real-time process monitoring, flexibility to tailor batch size for lean manufacturing, and improved operational safety as seen in other cutting edge pharmaceutical companies.

The upgraded facility is installed with a 600-liter bioreactor instead of a labor-intensive method using 100 x 6 liter flasks for the same size batch. Scaling up to the automated 600-liter bioreactor has eliminated ~ 80% of the manpower previously needed for this part of the process.

In March 2008, the company halted the manufacturing and marketing of Alferon N Injection® due to the high labor cost for manufacturing Alferon® and the low capacity significantly limiting the commercialization potential of Alferon N Injection®. The original process, producing the Alferon® in hundreds of small flasks, was extremely labor intensive. The upgraded manufacturing facility which uses a 600-liter bioreactor will provide a cost effective process and provide the capacity to supply both the US and South American market. The FDA will need to re-affirm the amended Biological License Application (BLA) for the facility before the commercial sales of Alferon N Injection® are recommenced. The company is anticipating having commercial product available for distribution by Armada Healthcare by late 2015.

According to industry sources, global sales of interferon (from multiple manufacturers) was approximately $7.8 billion in year 2013, with about two-thirds of global sales generated in the US. A review summarized and analyzed the clinical outcomes following treatment of a wide range of diseases with recombinant interferons (r-IFNs) and/or natural interferons (n-IFNs) (Strayer, et al. Recombinant and Natural Human Interferons: Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies. J Interferon Cytokine Res 2012;32(3):95-102).

About Alferon® N

Alferon® N is the only natural source, multi-species alpha interferon currently approved for sale in the U.S. Alferon® N is approved in the U.S. only for the treatment of refractory or recurring external genital warts caused by human papilloma virus in patients 18 years of age or older.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities ("biological modifiers") for treatment of seriously debilitating disorders especially life-threatening viruses. Hemispherx's flagship products include Alferon® N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases including cancers. Because both Ampligen® and Alferon® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon® N Injection®), approved for sale in the U.S. and Argentina. The FDA approval of Alferon® N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company's Alferon N Injection® approval in Argentina includes the use of Alferon N Injection® (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net .

Disclosure Notice

Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. The production of new Alferon® API inventory will not commence until validation phases are complete. While the facility is approved by FDA under the Biological License Application ("BLA") for Alferon®, this status will need to be reaffirmed upon the completion of the facility's enhancements prior to commercial sale of newly produced inventory product. If and when we obtain a reaffirmation of FDA BLA status and have begun production of new Alferon® API, we will need FDA approval as to the quality and stability of the final product manufactured in the upgraded facility. The final results of these efforts could vary materially from Hemispherx's expectations. Dr. David Strayer is the Medical Director of Hemispherx Biopharma and author of the referenced review article.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "plans," and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Hemispherx that any of its plans will be achieved. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Hemispherx's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Examples of such risks and uncertainties include those set forth in the Disclosure Notice, above, as well as the risks described in Hemispherx's filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Hemispherx undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise revise or update this release to reflect events or circumstances after the date hereof. No evidence is suggested that Alferon® N, Alferon® LDO and/or Ampligen will ever be commercially approved for the new potential treatment indications mentioned in this release.

Company/Investor Contact Charles Jones CJones & Associates Public Relations Office: 888-557-6480 Cell: 305-987-7418 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Central Florida Buyers Face the Cash Reality First

Updated Category News Views 94

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 24

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 53

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 103

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Minnesota Giving Record Signals a Stressed Safety Net

Updated Category News Views 63

Thirty-eight million dollars landing in one day is no small civic heartbeat. Minnesota’s Give to the Max Day brought in a record $38.4 million in 2026 for nearly 6,000 nonprofits and schools, edging past the $37.8 million raised in 2025. More than 65,000 people gave. That deserves a clear-eyed nod, not a cynical shrug. Still, the number carries two messages at once. It...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 36

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 18

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading

Top 5 Most Recently Viewed Articles

BlackBerry QNX and Pi Square Join Forces to Advance Indian Tech

Updated Category News Views 333

BlackBerry QNX Partners with Pi Square Technologies BlackBerry Limited (NYSE: BB) is experiencing a notable increase in share prices, reflecting growing investor confidence. Expanding Horizons for Engineers Recently, BlackBerry’s QNX division announced an exciting multi-year collaboration with Pi Square Technologies. This initiative aims to train thousands of engineers...

Continue Reading
Investors Urged to Act: Investigating DexCom Securities Claims

Updated Category News Views 67

Understanding the Ongoing Investigations into DexCom Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims on behalf of investors affected by losses in DexCom, Inc. (NASDAQ: DXCM). This inquiry is a direct response to significant concerns raised about the company's business practices and market performance. The Scope...

Continue Reading
Legal Battle Heats Up for Michigan Auto Attorney Over CURE

Updated Category News Views 299

Michigan Attorney Faces Legal Challenges Amid CURE Controversy In a recent turn of events, an attorney from Michigan is experiencing the challenges of navigating legal waters after speaking out against CURE Auto Insurance. The attorney, Steven M. Gursten, along with his firm Michigan Auto Law, is embroiled in lawsuits that highlight serious concerns about consumer...

Continue Reading
Investors of Joint Stock Company Kaspi.kz (KSPI) Take Action Now

Updated Category News Views 120

Investors of Joint Stock Company Kaspi.kz (NASDAQ: KSPI) Take Action Attention investors of Joint Stock Company Kaspi.kz, also known as KSPI! A recent report has raised serious concerns regarding the company's activities, prompting investors who have experienced losses to consider their options in filing a securities fraud lawsuit. These troubling developments are crucial...

Continue Reading
Investors Guide: Urgent Action Needed for Western Asset Fund

Updated Category News Views 130

Introduction to the Class Action The Rosen Law Firm, a prominent name in investor rights advocacy, is urging investors in the Western Asset Management Company mutual funds to take action before an important deadline. If you invested in the 'Western Asset US Core Bond Fund' or the 'Western Asset Core Plus Bond Fund' during the designated class period, this message is...

Continue Reading